載入...
Phase II Study of Docetaxel and Celecoxib, a Cyclooxygenase-2 Inhibitor, in Elderly or Poor Performance Status (PS2) Patients with Advanced Non-small Cell Lung Cancer
INTRODUCTION: The utility of two-drug chemotherapy regimens in elderly or performance status (PS 2) patients with advanced non-small cell lung cancer (NSCLC) remains to be established. Preclinical studies suggested that celecoxib, a Cyclooxygenase-2 inhibitor, has antitumor activity in NSCLC and can...
Na minha lista:
| Main Authors: | , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2008
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3859308/ https://ncbi.nlm.nih.gov/pubmed/18978565 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e31818b194e |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|